Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 2.6% – Should You Sell?

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) fell 2.6% on Thursday . The stock traded as low as $0.35 and last traded at $0.38. 36,840,297 shares were traded during mid-day trading, an increase of 23% from the average session volume of 30,057,420 shares. The stock had previously closed at $0.39.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on Tonix Pharmaceuticals in a research note on Monday. They set a “hold” rating on the stock.

Tonix Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The company has a market cap of $69.23 million, a PE ratio of -0.01 and a beta of 2.23. The business has a fifty day simple moving average of $0.22 and a two-hundred day simple moving average of $0.41.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.03) by $1.80. The company had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. Research analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.